The Lymphoma SPORE Developmental Research Program supports innovative translational research projects that may develop into full projects. To achieve this objective, the Developmental Research Program will solicit submission of novel projects with translational potential in lymphoma and CLL. Candidate projects will be reviewed by a panel with expertise in translational research, and the most promising proposals will be selected for support with the intent that they will either develop into full SPORE projects or secure peerreviewed funding as independent projects. The leaders of developmental projects will be fully incorporated into the SPORE and be able to take advantage of the expertise of SPORE investigators in bench to bedside translation. In the last 4 years the DRP has supported a broad portfolio of projects from 8 different departments at BCM and 3 at TMH, as well as from other institutions in the Texas Medical Center (one award to Rice University and one in collaboration with MD Anderson). DRP projects have produced 25 publications and have been leveraged to obtain 10 new peer-reviewed grants.The program directors, in collaboration with the Administrative Core will continue to use this program to test and develop novel strategies. We will continue to collect data to evaluate the success of the DRP program, allowing evaluation by the lAB and EAB. Two projects in this SPORE renewal have an aim that developed from a Developmental Research Program project, indicating past success.

Public Health Relevance

Tfie program supports innovative and scientifically meritorious pilot projects to explore novel ideas in lymphoma and CLL research. These pilot studies may develop into full projects if they demonstrate potential to be translated into clinicallyi important applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA126752-06
Application #
8395287
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
6
Fiscal Year
2012
Total Cost
$165,756
Indirect Cost
$72,324
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108
Nabekura, Tsukasa; Chen, Zhiying; Schroeder, Casey et al. (2018) Crk Adaptor Proteins Regulate NK Cell Expansion and Differentiation during Mouse Cytomegalovirus Infection. J Immunol 200:3420-3428
Shum, Thomas; Kruse, Robert L; Rooney, Cliona M (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther 18:653-664
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
McLaughlin, Lauren P; Rouce, Rayne; Gottschalk, Stephen et al. (2018) EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132:2351-2361
McClain, Kenneth L; Picarsic, Jennifer; Chakraborty, Rikhia et al. (2018) CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 124:2607-2620
Gomes-Silva, Diogo; Ramos, Carlos A (2018) Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line. Biotechnol J 13:

Showing the most recent 10 out of 270 publications